Unique ID issued by UMIN | UMIN000031296 |
---|---|
Receipt number | R000035727 |
Scientific Title | A phase I clinical pharmacology study of SJP-0125 |
Date of disclosure of the study information | 2018/03/14 |
Last modified on | 2019/02/14 18:27:44 |
A phase I clinical pharmacology study of SJP-0125
A phase I clinical pharmacology study of SJP-0125
A phase I clinical pharmacology study of SJP-0125
A phase I clinical pharmacology study of SJP-0125
Japan |
Primary open-angle glaucoma (broad definition) or ocular hypertension
Ophthalmology |
Others
NO
To evaluate the pharmacokinetics and safety of SJP-0125 compared to 0.1% brimonidine tartrate or 1% brinzolamide ophthalmic solution administered one drop once a day for 1 day to healthy subjects
Pharmacokinetics
Pharmacokinetics of SJP-0125
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
3
Treatment
Medicine |
One drop of SJP-0125 is instilled into each eye once a day (in the morning) for 1 day.
One drop of 0.1% brimonidine tartrate ophthalmic solution is instilled into each eye once a day (in the morning) for 1 day.
One drop of 1% brinzolamide ophthalmic solution is instilled into each eye once a day (in the morning) for 1 day.
20 | years-old | <= |
35 | years-old | >= |
Male and Female
1)Written informed consent obtained after adequate explanation on participating the study
2)Japanese male or female aged 20 to 35 years at consent
3)Able and willing to adhere the study instructions to the subjects defined in the protocol and the study schedule
4)IOP >= 10 mmHg and =< 20 mmHg in each eye, and asymmetry of IOP not greater than 5 mmHg
1)Presence of any disease irrespective of receiving medical treatment
2)History of a serious systemic disease
3)History of a serious psychiatric disorder
4)History of ocular surgery or history of ocular injury considered to be inappropriate to participate in the study
5)History of drug allergy
6)Use of any drugs within 14 days prior to the start of the study treatment
7)Males or females who made blood donation of 400 mL or more within 84 days or 112 days, respectively, prior to the start of the study treatment
8)Participated in any other clinical trial within past 90 days and received any other investigational drug or plans to participate in any other clinical trial during the study
9)Presence of abnormal ophthalmologic findings
10)Anticipated wearing of any contact lenses
11)Best corrected acuity <1.0
12)Body mass index < 18.5 or >= 25.0
13)Females who are pregnant, breastfeeding, or potentially pregnant. Or females who desire to be pregnant or males whose partners desire to be pregnant, or males or females who do not intend to use a reliable means of contraception from consent to the end of the study
14)Prior ocular instillation of SJP-0125
18
1st name | |
Middle name | |
Last name | Makoto Aihara |
The University of Tokyo
Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine
7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan
03-5800-6415
aihara-tky@umin.net
1st name | |
Middle name | |
Last name | Takuro Sekiya |
Senju Pharmaceutical Co.,Ltd.
Clinical Development
3-1-9, Kawara-machi, Chuo-ku, Osaka, Japan
06-6201-9605
t-sekiya@senju.co.jp
Senju Pharmaceutical Co.,Ltd.
Senju Pharmaceutical Co.,Ltd.
Profit organization
NO
2018 | Year | 03 | Month | 14 | Day |
Unpublished
Completed
2018 | Year | 01 | Month | 11 | Day |
2018 | Year | 03 | Month | 14 | Day |
2018 | Year | 02 | Month | 14 | Day |
2019 | Year | 02 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035727